Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 2:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 1,357 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Resolution Clear all
Completed Phase 2 Interventional Results available

Safety and Efficacy of BRM421 for Dry Eye Syndrome

NCT03066219
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
BRM421, Placebo
Drug
Lead sponsor
BRIM Biotechnology Inc.
Industry
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
2
States / cities
Lewiston, Maine • Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 28, 2026, 2:05 PM EDT
Completed Not applicable Interventional

Comparison of 3 Novel Contact Lens Solutions on the Basal Lamina

NCT00691457
View directory record Official record
Conditions
Contact Lens Solution
Interventions
Opti-Free contact lens solution, ReNu Multiplus contact lens solution, Clear Care contact lens solution
Device
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Virginia Beach, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 1, 2012 · Synced Oct 28, 2026, 2:05 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Point of Care, High Resolution and 3-Dimensional Ultrasonography

NCT05282212
View directory record Official record
Conditions
Bone Loss in Jaw, Dental Diseases
Interventions
Ultrasound Scan
Diagnostic Test
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Oct 28, 2026, 2:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Safety of Topical Administration of Brimonidine Tartrate Ophthalmic Solution 0.025%.

NCT02039765
View directory record Official record
Conditions
Hyperemia
Interventions
Brimonidine tartrate
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Oct 28, 2026, 2:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Comparison Of A Single PF-04634817 Tablet Dose Compared With A Solution In Healthy Volunteers

NCT01247883
View directory record Official record
Conditions
Healthy
Interventions
PF-04634817
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 2, 2011 · Synced Oct 28, 2026, 2:05 PM EDT
Completed Phase 1Phase 2 Interventional

Safety and Efficacy Trial to Treat Open-Angle Glaucoma or Ocular Hypertension

NCT01279083
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
DE-112, DE-112 Vehicle Solution, Timolol Maleate Solution
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Austin, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 17, 2012 · Synced Oct 28, 2026, 2:05 PM EDT
Completed Phase 1Phase 2 Interventional

A Phase 1/2, RU-101 Ophthalmic Solution in Patients With Severe Dry Eye

NCT01843894
View directory record Official record
Conditions
Dry Eye
Interventions
RU-101
Biological
Lead sponsor
R-Tech Ueno, Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Oct 28, 2026, 2:05 PM EDT
Completed Not applicable Interventional Results available

Use of High-Resolution Microendoscopy (HRME) in Patients With Adenocarcinoma In-Situ (AIS) of the Cervix

NCT02206048
View directory record Official record
Conditions
Cervix Carcinoma
Interventions
Proflavine, High-Resolution Microendoscopy (HRME) Imaging
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
21 Years to 64 Years · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Oct 28, 2026, 2:05 PM EDT
Active, not recruiting Phase 3 Interventional

Long Term Extension Study in Patients With Primary Hyperoxaluria

NCT04042402
View directory record Official record
Conditions
Primary Hyperoxaluria Type 1 (PH1), Primary Hyperoxaluria Type 2 (PH2), Kidney Diseases, Urologic Diseases, Genetic Disease, Primary Hyperoxaluria Type 3 (PH3)
Interventions
DCR-PHXC
Drug
Lead sponsor
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Industry
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
4
States / cities
San Francisco, California • Boston, Massachusetts • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 28, 2026, 2:05 PM EDT
Completed Phase 3 Interventional Results available

Aztreonam for Inhalation Solution vs Tobramycin Inhalation Solution in Patients With Cystic Fibrosis & Pseudomonas Aeruginosa

NCT00757237
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Aztreonam for Inhalation Solution (AZLI), Tobramycin Inhalation Solution (TIS)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
6 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
29
States / cities
Anchorage, Alaska • Phoenix, Arizona • Tuscon, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2011 · Synced Oct 28, 2026, 2:05 PM EDT
Not listed Early Phase 1 Interventional

The Effects and Safety of Topical Spironolactone Ophthalmic Solution, 0.005 mg/cc in Subjects With Dry Eye Disease

NCT05995392
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Topical spironolactone ophthalmic solution, 0.005 mg/cc, Placebo
Drug
Lead sponsor
Richard W Yee, MD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Bellaire, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 28, 2026, 2:05 PM EDT
Completed Phase 4 Interventional

Omidria and Dexycu, or Omidria and Dextenza Compared to Topical Prednisolone Acetate 1% Following Cataract Surgery

NCT04316936
View directory record Official record
Conditions
Cataract Surgery
Interventions
Omidria, Dextenza (dexamethasone ophthalmic insert) 0.4mg, Dexycu, 9% Intraocular Suspension, Prednisolone Acetate 1%
Drug
Lead sponsor
Silverstein Eye Centers
Other
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 28, 2026, 2:05 PM EDT
Terminated No phase listed Observational

Establishing a Correlation Between HRM and UGI MM Studies

NCT06314893
View directory record Official record
Conditions
Esophageal Motility Disorders
Interventions
Not listed
Lead sponsor
Lexington Health Incorporated
Other
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
West Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Oct 28, 2026, 2:05 PM EDT
Completed Phase 1 Interventional

Study of the Safety and Tolerability of P 321 Ophthalmic Solution in Subjects With Dry Eye Disease

NCT02242032
View directory record Official record
Conditions
Dry Eye Disease
Interventions
P-321 Ophthalmic Solution, P-321 Ophthalmic Solution placebo
Drug
Lead sponsor
Parion Sciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Artesia, California
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Oct 28, 2026, 2:05 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Wellness & Workforce Solution for Lupus/Lupus Nephritis

NCT06217107
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Micro-learning content, Health360x app, Culturally congruent coaching
Behavioral
Lead sponsor
Morehouse School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 28, 2026, 2:05 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Participants With Ocular Redness

NCT01959230
View directory record Official record
Conditions
Hyperemia
Interventions
Brimonidine Tartrate, Vehicle, Sodium Fluorescein, Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 23, 2019 · Synced Oct 28, 2026, 2:05 PM EDT
Recruiting Not applicable Interventional

Low Intensity Focused Ultrasound for Chronic Pain: High Resolution Targeting of The Human Insula

NCT06906211
View directory record Official record
Conditions
Chronic Back Pain, Chronic Pain (Back / Neck)
Interventions
low intensity focused ultrasound (LIFU)
Device
Lead sponsor
Washington D.C. Veterans Affairs Medical Center
Federal
Eligibility
21 Years to 75 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 28, 2026, 2:05 PM EDT
Completed Phase 2 Interventional

Atropine Eye Drops for Watery Eyes (Excessive Tearing)

NCT07676981
View directory record Official record
Conditions
Epiphora
Interventions
Atropine ophthalmic solution
Drug
Lead sponsor
Rehan Ahmed
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Houston, Texas • Mesquite, Texas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 28, 2026, 2:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Repeat Insult Patch Test (RIPT) Study Evaluating the Sensitization Potential of Topical SM04755 Solution in Healthy Volunteers

NCT03502434
View directory record Official record
Conditions
Tendinopathy
Interventions
SM04755, Vehicle, White Petrolatum, Sodium lauryl sulfate
Drug · Other
Lead sponsor
Biosplice Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Lynchburg, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 28, 2026, 2:05 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Bepotastine Besilate Ophthalmic Solution in Allergic Conjunctivitis

NCT00586664
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Bepreve (bepotastine besilate ophthalmic solution) 1.5%, placebo comparator, Bepotastine Besilate Ophthalmic Solution 1.0%
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
10 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Feb 8, 2013 · Synced Oct 28, 2026, 2:05 PM EDT
Not listed Phase 1 Interventional

Safety and TDM of Continuous Infusion Vancomycin Through Continuous Renal Replacement Therapy Solution

NCT02663596
View directory record Official record
Conditions
Pediatric Continuous Renal Replacement Therapy, Dialysis, Renal Failure
Interventions
Vancomycin
Drug
Lead sponsor
Drexel University
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 28, 2026, 2:05 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Acquisition and Clinical Image Evaluation of Fujifilm's High Resolution (HR) Digital Breast Tomosynthesis (DBT) Images.

NCT07471750
View directory record Official record
Conditions
Routine Screening Mammography
Interventions
DBT HR mode image acquisition
Device
Lead sponsor
Fujifilm Medical Systems USA, Inc.
Industry
Eligibility
40 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 28, 2026, 2:05 PM EDT
Completed Not applicable Interventional

Diabetes Education/Skills Training and Social Needs Resolution Intervention

NCT05935410
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
DM Social Needs, Usual Care
Behavioral
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
50 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 28, 2026, 2:05 PM EDT
Withdrawn Phase 4 Interventional

Use of Bismuth Subsalicylate in Clostridium Difficile Colitis

NCT03592082
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Bismuth Subsalicylate, standard antibiotic therapy
Drug
Lead sponsor
Bassett Healthcare
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Cooperstown, New York
Source: ClinicalTrials.gov public record
Updated Jul 19, 2018 · Synced Oct 28, 2026, 2:05 PM EDT